CD19+CXCR5 CAR-T cells

CD19+CXCR5 CAR-T cells are a form of chimeric antigen receptor T cell (CAR-T) therapy engineered to express both a CAR targeting the B-cell marker CD19 and the chemokine receptor CXCR5. The addition of CXCR5 is designed to enhance the migration and homing of these T cells to lymphoid tissues, where B-cell lymphomas often reside. This dual modification aims to improve antitumor efficacy by overcoming barriers such as poor infiltration into tumor sites—a limitation observed with conventional CD19-targeted CAR-T therapies in lymphoma. In a phase I clinical trial for relapsed or refractory B-cell lymphoma, these modified T cells demonstrated an objective response rate of 80% and a complete response rate of 50%, with manageable safety profiles (mainly grade 1–2 cytokine release syndrome). The therapy is investigational and not yet approved for routine clinical use[1].

Other names

CXCR5-modified CD19 CAR-T cellsCXCR-5-modified CD19 CAR-T cellsCXCR 5-modified CD19 CAR-T cellsCXCR5-expressing CD19 CAR-T cellsCXCR-5-expressing CD19 CAR-T cellsCXCR 5-expressing CD19 CAR-T cellsCD19-CXCR5 CAR-TCD-19-CXCR5 CAR-TCD 19-CXCR5 CAR-T